Denver News Updates

Chronic Obstructive Pulmonary Disease Pipeline Insight Report | 70+ Companies and 70+ Pipeline Drugs

 Breaking News
  • No posts were found

Chronic Obstructive Pulmonary Disease Pipeline Insight Report | 70+ Companies and 70+ Pipeline Drugs

January 16
17:48 2023
Chronic Obstructive Pulmonary Disease Pipeline Insight Report | 70+ Companies and 70+ Pipeline Drugs

DelveInsight’s, “Chronic Obstructive Pulmonary Disease Pipeline Insight 2023” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Obstructive Pulmonary Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report

  • DelveInsight’s Chronic Obstructive Pulmonary Disease Pipeline report depicts a robust space with 7o+ active players working to develop 70+ pipeline therapies for chronic obstructive pulmonary disease treatment.
  • The leading Chronic Obstructive Pulmonary Disease Companies are working in the market include Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma,   Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, and others are developing novel drug candidates to improve the chronic obstructive pulmonary disease treatment landscape.
  • Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies include SB240563, SAR440340, Dupilumab, CHF 6001, Tyvaso DPI, Ensifentrine, Benralizumab, MV130, YPL 001, PUL-042 Inhalation Solution, SelK2, Batefenterol, Tezepelumab, QBW251, GSK3277511A, Anti-ST2, MEDI3506, Ivacaftor, Emeramide, CSJ117, BCT197, AZD8871, SNG001, APC-1000, Quercetin, CHF6366, Bronchial basal cells, ACT-541468, UMC119-06, PUR1800, Lemborexant, GSK3923868, GRC 39815, EP395, 610, DMX-700,  CM326, LABP-73,  KN-002 and others.
  • Chronic Obstructive Pulmonary Disease Companies and academics are working to assess challenges and seek opportunities that could influence Chronic Obstructive Pulmonary Disease R&D. The Chronic Obstructive Pulmonary Disease pipeline therapies under development are focused on novel approaches to treat/improve Chronic Obstructive Pulmonary Disease.

 

Discover the recent breakthroughs and advances in Chronic Obstructive Pulmonary Disease Drug Treatment @ Chronic Obstructive Pulmonary Disease Pipeline Outlook

 

Recent Developmental Activities in the Chronic Obstructive Pulmonary Disease Treatment Landscape

  • In June 2022, the US Food and Drug Administration assigned an Investigational New Drug application (IND) number to Therapeutic Solutions International experimental JadiCell therapy. The FDA has not yet approved the company’s IND application.
  • In June 2022, Verona Pharma announced completion of the patient enrolment – with more than 800 subjects involved – for its randomised ENHANCE-1 trial The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease . It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year and further data from ENHANCE-2 in the third quarter of 2022.
  • In May 2022, RS BioTherapeutics entered into a license agreement with Synthonics, Inc. for the exclusive, worldwide right to use Synthonics’ metal coordinated cannabinoid in nebulized form for the treatment of pulmonary inflammatory disorders. RS BioTherapeutics is developing its lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease.
  • In March 2022, Pulmatrix, Inc., announced positive top-line results of its recently completed Phase Ib clinical study of PUR1800, a narrow-spectrum kinase inhibitor (NSKI) administered as a dry powder for inhalation with iSPERSE  for evaluation in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is being developed to treat Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD). Initial safety and pharmacokinetics (PK) were evaluated in patients with stable COPD.
  • In September 2021, Renovion and the COPD Foundation announced the creation of a new partnership to accelerate the development of a novel therapy for the treatment of excessive airway mucus and inflammation in individuals with chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis (CF) bronchiectasis. 
  • In August 2021, EpiEndo Pharmaceuticals announced the closing of a €20m Series A financing round led by Flerie Invest and Iðunn Venture Fund, with existing investors ABC Ventures participating, along with the European Innovation Council (EIC) Fund joining the round. The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication. In May 2022, the company completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects.
  • In May 2021, vTv Therapeutics LLC entered into an exclusive licensing agreement with Newsoara Biopharma  for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea.  Under the terms of the agreement, vTv Therapeutics received an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara to develop HPP737 in the covered territories for respiratory and other inflammatory diseases, including COPD.

 

Chronic Obstructive Pulmonary Disease Pipeline Overview

Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases. Excessive Smoking is the leading risk factor for COPD. In addition, occupational and environmental exposure to chemical fumes, dust, and other lung irritants accounts for 10–20% of cases. People with a history of severe lung infections in childhood are more likely to develop COPD. Also, α1 antitrypsin deficiency is a rare cause of COPD. The most common symptom of COPD is chronic and progressive dyspnea. Production of cough and sputum is present in up to 30% patient population.

 

Find out more about chronic obstructive pulmonary disease therapies and drugs @ Chronic obstructive pulmonary disease Treatment Landscape

 

Chronic Obstructive Pulmonary Disease Emerging Drugs 

 

Benralizumab: AstraZeneca

Benralizumab (FASENRA) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophil and attracts natural killer cells to induce rapid and near-complete depletion of eosinophil via apoptosis (programmed cell death). The drug is approved by the US FDA for asthma and is currently being developed for other respiratory and immunological disorders such as COPD, atopic dermatitis, and others. The drug was earlier in GALATHEA and TERRANOVA trials (randomized, double-blinded, placebo-controlled, parallel-group trials that assessed the safety and efficacy of Fasenra 30mg and 100mg for preventing COPD exacerbations). At present, the drug is in RESOLUTE (Phase III trial) to evaluate its efficacy and safety.

 

MV130: Inmunotek S.L.

MV130 (BACTEK) is a bacterial mucosal vaccine or a bacterial polyvalent vaccine in a spray that is administered sublingually to treat recurrent respiratory tract infections in children and adults. MV130 plays a relevant role in modulating the functional activity of the innate and adaptive immune response by stimulating dendritic cells, which are part of innate immunity. A Phase III clinical trial is evaluating MV130 in patients with COPD. At present, the trial is ongoing in Spain.

 

SB-240563: GlaxoSmithKline

SB-240563 (mepolizumab) is a humanized monoclonal antibody that blocks human interleukin 5 (hIL-5) from binding to its receptor. Initial clinical studies investigated the safety and efficacy of SB-240563 for the treatment of asthma and atopic dermatitis (AD). SB-240563 reduced peripheral and tissue eosinophils in patients with asthma and healthy volunteers. Currently, it is in the Phase III stage of the clinical trials. 

 

SAR440340: Sanofi/Regeneron

SAR440340 (Itepekimab) is a humanized IgG4P monoclonal antibody that blocks human interleukin 33 (hIL-33) from binding to its receptor. IL-33 is an epithelial cytokine that initiates and amplifies innate and adaptive type 2 and 1 inflammatory pathways in response to epithelial insults due to exposure to allergens, viruses, cigarette smoke, and pollutants. SAR440340 was invented using Regeneron’s proprietary VelocImmune technology that yields optimized fully-human antibodies and is being developed jointly by Regeneron and Sanofi as part of a global collaboration agreement. 

 

CHF 6001: Chiesi Farmaceutici S.p.A.

CHF6001 is a novel inhaled phosphodiesterase-4 (PDE-4) inhibitor developed as an extrafine formulation (i.e., with mass median aerodynamic diameter  ≤ 2 μm) and low systemic exposure. This allows CHF6001 to reach a therapeutic concentration in the target organ, the lung, with reduced systemic exposure, limiting systemic adverse effects. The drug is administered through a dry powder inhaler (DPI NEXThaler).

 

YPL 001: Yungjin Pharm. Co., Ltd.

YPL 001 is a drug molecule that belongs to the anti-inflammatory and anti-histamine class of drugs. The drug is being developed for COPD. YPL-001 is a product developed using wild chives, which grow naturally in nature, as a raw material. A Phase II trial was conducted in US hospitals to assess the drug’s safety in patients with moderate-to-severe COPD. In Phase I studies, YPL-001 was well tolerated in healthy subjects following single (up to 320 mg) and multiple (up to 240 mg twice daily [BID]) oral doses with no serious adverse events (AEs).

 

Chronic Obstructive Pulmonary Disease Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

 

Learn more about the novel and emerging Chronic Obstructive Pulmonary Disease pipeline therapies and companies @ Chronic Obstructive Pulmonary Disease Ongoing Clinical Trials

 

Chronic Obstructive Pulmonary Disease Segmentation

The Chronic Obstructive Pulmonary Disease Pipeline report proffers an integral view of the Chronic Obstructive Pulmonary Disease emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report

  • Coverage- Global
  • Chronic Obstructive Pulmonary Disease Companies- RemeGen, SynCore Biotechnology, Allarity Therapeutics, Daiichi Sankyo Company, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Byondis B.V., Jiangsu Hansoh Pharmaceutical Co., Ltd., Shanghai Miracogen Inc., Ambrx, Inc., Daehwa Pharmaceutical Co., Ltd., Phoenix Molecular Designs, Menarini Group, Samus Therapeutics, Inc., Hanmi Pharmaceutical Company Limited, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Immutep Limited, Arvinas Inc., G1 Therapeutics, Mirati Therapeutics Inc., Chia Tai Tianqing Pharmaceutical, Shanghai Pharmaceuticals Holding Co., Ltd, Pfizer, OncoTherapy Science, Inc., Eisai Inc., Dizal Pharmaceuticals, Tyme, Inc, Orion Pharma, HiberCell, Inc., Rhizen Pharmaceuticals SA, Hutchison Medipharma Limited, OncoPep Inc., Taizhou Hanzhong biomedical co. LTD, Kind Pharmaceuticals LLC, Dantari, Inc., Veru Inc., Taiho Oncology, Eli Lilly and Company, Sermonix Pharmaceuticals, Merus N.V., Minerva Biotechnologies Corporation, Kintara Therapeutics, Inc., Sichuan Baili Pharmaceutical Co., Ltd.,  Regor Pharmaceuticals Inc., Tianjin Hemay Biotech, Jiangsu Simcere Pharmaceutical Co., Ltd., and others.
  • Chronic Obstructive Pulmonary Disease Pipeline Therapies- Disitamab Vedotin, EndoTAG®-1 (SB05), Stenoparib (2X-121), U3-1402, KN026, trastuzumab duocarmazine, HS-10342, MRG002, ARX788, DHP107, PMD-026, PVX-410, HX008, Tenalisib, MEN1611, SM-88, HMPL-013, ODM-209, HC-5404-FU, RP12146, PU-H71, NOV120101, SC10914, Eftilagimod Alpha, ARV-471, E7090, DZD1516, G1T38, Sitravatinib, TQ-B211, B003, PF-06873600, OTS167PO, AND019, DAN-222, Enobosarm, Futibatinib, LY3484356, Lasofoxifene, MCLA-128, huMNC2-CAR44 CAR T cells, REM-001, GNC-035, RGT-419B, Hemay022, SCR-6852, and others.
  • Chronic Obstructive Pulmonary Disease Segmentation: Phases, Mechanism of Action, Route of Administration, Molecule Type

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Obstructive Pulmonary Disease Overview
  4. Chronic obstructive pulmonary disease Pipeline Therapeutics
  5. Chronic obstructive pulmonary disease Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Benralizumab: AstraZeneca
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. YPL 001: Yungjin Pharm. Co., Ltd.
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I/II)
  13. CHF6366: Chiesi Farmaceutici
  14. Drug profiles in the detailed report…..
  15. Inactive Chronic obstructive pulmonary disease Products
  16. Chronic Obstructive Pulmonary Disease Key Companies
  17. Chronic Obstructive Pulmonary Disease Key Products
  18. Chronic Obstructive Pulmonary Disease Unmet Needs
  19. Chronic Obstructive Pulmonary Disease Market Drivers and Barriers
  20. Chronic Obstructive Pulmonary Disease- Future Perspectives and Conclusion
  21. Chronic Obstructive Pulmonary Disease Analyst Views
  22. Chronic Obstructive Pulmonary Disease Key Companies
  23. Appendix

 

Dive deep into rich insights into new Chronic Obstructive Pulmonary Disease Drugs, visit @ Chronic Obstructive Pulmonary Disease Key Companies and Pipeline Therapies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories